news
Positive results for Viking’s rare diseases in vivo study
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
List view / Grid view
Hit-to-Lead
news
Wellcome Trust gives Polyphor CHF 2.3 million for antibiotic development
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
news
‘Love hormone’ used a drug lead for inhibiting preterm labour
A team of scientists from Austria, Australia, Denmark, England and the Czech Republic, led by Christian Gruber from the MedUni Vienna's Institute of Pharmacology, managed to isolate a neuropeptide from ants that is very similar to the human love hormone oxytocin, and the closely related hormone vasopressin.
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
JPND launches €23 million call for neurodegenerative disease research
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
news
Global partnership launched to enable personalised therapies in multiple sclerosis
In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient.
news
Gut microbes linked to immunotherapy response in melanoma patients
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Patients with malignant melanoma are more likely to respond to immunotherapy treatment if they had greater diversity in their gut bacteria, according to...
news
Hookipa receives €4.16 million cancer grant from FFG
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The grant for the second year of a multi-year R+D project and will be used for Hookipa’s arenaviral vector technologies, cancer immunotherapies and to...
news
Charles River Laboratories acquires Agilux Laboratories, Inc.
13 October 2016 | By Charles River Laboratories
Enhances Charles River’s early-stage capabilities in bioanalytical services...
news
Asceneuron receives Parkinson’s research grant from the Michael J. Fox Foundation
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The grant from the MJFF therapeutic pipeline program will support studies for the optimisation of molecules to provide preclinical proof of concept in...
product
Cisbio Bioassays Kinases – A comprehensive platform of assays and reagents for evaluating kinase activity
4 October 2016 | By Cisbio
Cisbio Bioassays has developed several assays for covering all the needs for monitoring kinase targets...
whitepaper
Whitepaper: Uncover specific correlations in heterogeneous cell populations during drug development
Integrating the S3e™ Cell Sorter into sample preparation upstream of the QX200™ Droplet Digital System provided details about cell subpopulations that would have been undetectable in heterogeneous populations...
news
Antibiotics developed in 1960s show promise for Tuberculosis therapy
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Tuberculosis is the most deadly infectious disease in the world. Standard TB therapy takes at least 6 months and patients infected with multi-drug...
news
Quotient Clinical expands Data Sciences capability
27 September 2016 | By Quotient Clinical
Department moves into enhanced facility and increases headcount in response to continued demand for services...
news
Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute announce strategic partnership
26 September 2016 | By Charles River Laboratories
Partnership intends to accelerate translation of discoveries into novel therapies for patients...
